enfortumab vedotin + zimberelimab

Enfortumab vedotin + zimberelimab is an investigational combination therapy comprising two agents: **enfortumab vedotin**, an antibody-drug conjugate targeting Nectin-4 and delivering the cytotoxic agent monomethyl auristatin E (MMAE), and **zimberelimab**, a fully human monoclonal antibody targeting programmed cell death protein 1 (PD-1). This combination is being explored in clinical trials for its potential anti-tumor effects through dual mechanisms: direct tumor cell killing (via enfortumab vedotin) and immune checkpoint blockade (via zimberelimab) to enhance anti-tumor immune response. Zimberelimab is primarily developed by Gilead/Arcus Biosciences, distinct from pembrolizumab or other PD-1 inhibitors.